Key result
Following myocardial infarction, patients developing heart failure > functional class II experienced more frequent one-year unfavorable outcomes compared to those with mild or no heart failure.
Why the study?
An increasing number of post-myocardial infarction patients contributes to a higher long-term incidence of chronic cardiovascular diseases, prompting the need to identify key clinical and functional markers characterizing acute and chronic heart failure after myocardial infarction.
Cohort (n=186)
Answers are grounded in this paper and cite their sources.
Patients developing significant chronic heart failure (NYHA > II) after myocardial infarction have a higher risk of adverse outcomes at 1 year, and subanalysis suggests ARNI therapy may reduce cardiovascular death compared to enalapril in this population.
Вackground. The last decade has seen an increase in the number of people who have had myocardial infarction (MI). This phenomenon contributes to an increase in the long-term incidence of chronic cardiovascular diseases, including chronic heart failure. Purpose of the study. To identify the most significant clinical and functional indicators characterizing acute and chronic heart failure after myocardial infarction. Patient Characterization and Research Methods. This analysis included 186 patients who had myocardial infarction from January 2019 to January 2020: 86 people, the main subgroup, with signs of CHF above FC 2 (NYHA) (mean age 64.3 g) and 100 people, the comparison subgroup, without signs of CHF or had CHF 1 FC (NYHA) (mean age 62.6 l). After 1 year, clinical outcomes were assessed: cardiovascular death, repeated hospitalizations due to decompensation of CHF, death from other causes, stroke, repeated myocardial infarction, unplanned coronary revascularization. Results. In the acute period of myocardial infarction in the main subgroup (MI + CHF more than 2cl NYHA), all patients had symptoms of acute heart failure (AHF) in the form of Killip II and Killip III. Predictors of the development of chronic heart failure were the presence of a history of ischemic heart disease, confirmed in accordance with the recommendations, before myocardial infarction; decreased fraction of the left ventricle, detected before discharge and on the 30th day of myocardial infarction; the presence of atrial fibrillation (AF). One-year unfavorable outcomes in the main group were significantly more frequent. Subanalysis of long-term drug therapy showed that cardiovascular death was significantly less common in the subgroup of patients taking ARNI than in the subgroup of enalapril. Conclusion. In the present study, we studied postinfarction myocardial remodeling, which is realized in the form of the formation of a syndrome of acute and chronic heart failure. It has been shown that immediate reperfusion and restriction of the necrosis zone, as well as long-term use of drugs that inhibit SAS and RAAS, stimulating NPP, can inhibit the development of AHF and death. The CHF problem requires further fundamental research in order to develop new approaches that can affect more subtle mechanisms, such as the expression of specific genes involved in the disease, in order to reduce the persisting excess mortality for this pathology.
No takes yet. Share an insight, caveat, or question.
Ложкина et al. (2021) conducted a cohort in myocardial infarction (n=186). Heart failure > NYHA class II vs. No heart failure or NYHA class I was evaluated on One-year unfavorable outcomes (cardiovascular death, repeated hospitalizations due to decompensation of CHF, death from other causes, stroke, repeated myocardial infarction, unplanned coronary revascularization). Following myocardial infarction, patients developing heart failure > functional class II experienced more frequent one-year unfavorable outcomes compared to those with mild or no heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: